Pegaptanib sodium for the treatment of neovascular age-related macular degeneration (Q33216197)

24 July 2017

1 reference

title

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration (English)

1 reference

24 July 2017

1 reference

2

Carmen A Puliafito

1 reference

24 July 2017

1

Andrew A Moshfeghi

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Investigational Drugs

24 July 2017

published in

1 reference

24 July 2017

volume

14

1 reference

24 July 2017

issue

5

1 reference

24 July 2017

page(s)

671-682

1 reference

Pegaptanib for neovascular age-related macular degeneration

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Retinal angiomatous proliferation in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

BDNF reduces the retinal toxicity of verteporfin photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.5.671

10.1517/13543784.14.5.671

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference